Last month, medical device company Ivenix received clearance for a new smart infusion pump meant to address the safety issues endemic to the industry with more streamlined and intuitive technology.
Remember in July when the FDA issued an advisory warning of security flaws in Hospira's Symbiq smart infusion pumps? It apparently was a long time in the making, as "Hacking Healthcare," the cover story in the Nov. 16 issue of Bloomberg Businessweek, chronicles.
Break down the silos. Take control of your provider data.
This week, MedCity News covered a range of subjects, including hacking infusion pumps, pregnancy screening for genetic diseases, wearables to manage neurological disorders and the Feds trying to access Lance Armstrong's medical records.
We figured it would not be long until Hospira defended the security of its LifeCare PCA infusion pump.
The Food and Drug Administration on Friday issued an alert warning that Hospira's Symbiq Infusion System smart pumps could be vulnerable to hackers,a and recommended that healthcare facilities phase out use of the devices.
Shire adds to eye treatment portfolio with biotherapeutic deal and FDA issues safety alert for a Hospira infusion pump over concerns that it is vulnerable to a cyberattack.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
The advancement of biosimilars moves another step forward today with the launch of versions of a rheumatoid arthritis and Crohn’s disease drug to European markets. The products, which come from South Korean firm Celltrion and its partners Hospira and Mundipharma, will be in competition with the Johnson & Johnson and Merck & Co. drug Remicade. […]
Leading newspapers, including the Wall St. Journal and New York Times, misunderstand the strategy behind Pfizer’s proposed purchase of Hospira. Here’s what the Journal had to say: Pfizer Inc. said Thursday it would buy smaller rival Hospira Inc. in a $16 billion deal that would transform the New York pharmaceutical company into a leading player […]
In a move to grow its biosimilar business, Pfizer just bought hospital drug supplier Hospira for $17 billion. In a way, it’s Pfizer’s do-over in miniature of its failed, $100 billion attempt last year to merge with AstraZeneca – so many of the same conversation points from that era. A Wall Street Journal article from last April wrote […]
An unlikely candidate is at the center of a capital punishment debate: propofol, the anesthesia many physicians use to put patients under. Why? A shortage on the anesthetic drugs used for lethal injection caused state governments to look elsewhere for sedatives, the Scientific American reports. Propofol, used up to 50 million times a year in US […]
Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors.
Propofol might best be known as the anesthetic Michael Jackson used inappropriately as a sleeping aid. Administered properly, the drug widely is used in hospitals to sedate patients. It also happens to be part of an industrywide drug shortage affecting hospitals throughout the country. Injectable drugs maker Hospira (NYSE:HSP) is among the dwindling number of […]
The impact of drug shortages that have left doctors and patients scrambling for life-saving drugs became much more personal and real today at a U. S. Food and Drug Administration news conference. Nebraska mother Sara Stuckey spoke at the event on behalf of her 6 -year-old son Nate, who needs a leukemia drug to survive. […]
Hospira‘s (NYSE:HSP) beleaguered Rocky Mount, North Carolina manufacturing facility has been a drag on the company’s production and its 2011 financial results, and by the looks of the company’s 2012 guidance, the site will operate below capacity for the foreseeable future as Hospira works to regain regulatory compliance. Given the extent of the problems at […]
Hospira (NYSE:HSP) completed a two-year “restructuring and optimization plan” this year that the company expressly stated would increase shareholder value by generating annualized savings between $110 million and $140 million. But now the company faces a phalanx of angry shareholders claiming the company did not disclose the extent of problems at a North Carolina plant […]
Hospira (NYSE:HSP) plans to spend up to $375 million over the next three years to bring its manufacturing facilities into regulatory compliance, the bulk of it going to a North Carolina plant saddled under heavy regulatory scrutiny for much of the last two years. The effort is under way with a hiring blitz over the […]